INTRODUCTION
Daclizumab high-yield process (HYP) is a humanized monoclonal antibody targeted against CD25, the interleukin 2 receptor alpha subunit [1] . Interleukin 2 is a cytokine produced by activated T cells that regulates both immune responses and the maintenance of self-tolerance [2] . Blockade of CD25 showed promising results in T cell-mediated autoimmune disorders, including in pilot studies in multiple sclerosis (MS) [3] [4] [5] .
Subsequently, the efficacy and safety of daclizumab HYP have been evaluated in clinical studies in relapsing-remitting MS (RRMS) [6, 7] .
In the pivotal 1-year SELECT study (ClinicalTrials.gov identifier, NCT00390221), daclizumab HYP 150 mg subcutaneous (SC) every 4 weeks significantly reduced relapses, 12-week confirmed disability progression, and brain lesions on magnetic resonance imaging (MRI) compared with placebo [6] . Daclizumab HYP also showed superior efficacy to interferon (IFN) beta-1a 30 mcg intramuscular (IM) once weekly with respect to annualized relapse rate, MRI lesion activity, and 24-week confirmed disability progression over 2-3 years of treatment in the active-comparator phase 3 DECIDE study (ClinicalTrials.gov identifier, NCT01064401) [7] . Based on the safety profile of daclizumab HYP in SELECT [6] , one of the adverse events (AEs) of interest in DECIDE was cutaneous AEs. The objective of this report is to provide a description of the frequency and character of cutaneous AEs in DECIDE.
METHODS
Standard Protocol Approvals,
Registrations, and Patient Consents
The DECIDE study protocol was approved by central and local ethics committees, and the study was conducted in accordance with the
International Conference on Harmonisation
Guideline for Good Clinical Practice and the Declaration of Helsinki of 1964, as revised in 2008 [8] . DECIDE was registered at ClinicalTrials.gov (NCT01064401). All patients provided written informed consent before participating in the study and before photographs were used for educational purposes.
Trial Design and Patients
DECIDE was a multicenter, randomized, double-blind, double-dummy, active-controlled, phase 3 study to evaluate the efficacy and safety of daclizumab HYP versus IM IFN beta-1a [7] . The study design and patient eligibility criteria have been previously reported [7] . Briefly, patients with a confirmed diagnosis of RRMS (2005 McDonald criteria 1-4) [9] were randomized 1:1 to receive daclizumab HYP 150 mg SC every 4 weeks or IFN beta-1a 30 mcg IM once weekly for a minimum of 96 weeks up to a maximum of 144 weeks. The study ended when the last enrolled patient completed 96 weeks of treatment.
Safety Assessments
Treatment-emergent AEs and serious AEs, defined as events that started after the first dose of study drug and up to 180 days after the last dose, were monitored, classified, and recorded by investigators throughout the study. Serious AEs were followed until the event resolved, stabilized, or returned to baseline, even in patients who had completed or discontinued the study.
Investigators assessed AE severity (mild, moderate, severe), whether AEs and serious AEs were or were not related to study treatment, and whether an AE met the criteria for a serious AE based on guidance in the protocol (please see 
Cutaneous AE Onset and Severity
Treatment-emergent cutaneous AEs were reported at generally stable rates in both groups when analyzed by 12-week intervals over 96 weeks of treatment, although the rates were consistently higher with daclizumab HYP than with IM IFN beta-1a (Fig. 1a) . The cumulative incidence of cutaneous AEs was 37% in the daclizumab HYP group compared with 19% in the IM IFN beta-1a group over the course of the study. During the 6-month period after the last dose of study treatment, the incidence of cutaneous AEs remained higher in the daclizumab HYP group (21%) compared with the IM IFN beta-1a group (5%), but was similar between the groups beyond 6 months after the last dose (daclizumab HYP, \1%; IM IFN beta-1a, \1%). Cutaneous AEs were more frequently assessed by the investigator as being related to study treatment in daclizumab HYP-treated patients (15%) than in IM IFN beta-1a-treated patients (7%).
The most common cutaneous AEs (C2% of patients in either treatment group) are listed in Table 1 . Dermatitis, eczema, and rashes were among the most common investigator-reported Preferred Terms for cutaneous AEs (Table 1 ).
There was a 1.5-to 2.0-fold higher incidence of cutaneous AEs in patients with a medical history of rash, dermatitis, eczema, or psoriasis (Table 2 ). Most patients with cutaneous AEs had no action taken with their study drug as a result of the event (daclizumab HYP, 80.5%; IM IFN beta-1a, 89.8%; Table 2 ). The majority of patients with cutaneous AEs had events that were mild or moderate in severity (daclizumab HYP: 94%, 323/344; IM IFN beta-1a: 98%, 173/176). The most common mild and moderate cutaneous AEs (C2% of patients in either treatment group) are listed in Table 3 . Severe cutaneous AEs were more (Fig. 1b) ; however, the overall incidence of moderate or severe cutaneous AEs was higher with daclizumab HYP than with IM IFN beta-1a over the duration of the study (see Figure S1 ). (Fig. 2) .
Serious Cutaneous AEs
Serious cutaneous AEs were reported in 14 (2%) daclizumab HYP-treated patients and one (\1%) IM IFN beta-1a-treated patient. In the The categories are mutually exclusive, and an event was counted in only one category starting with the worst category as follows: drug withdrawn, then dose interrupted, then no action AE adverse event, HYP high-yield process, IFN interferon, IM intramuscular daclizumab HYP group, dermatitis and angioedema were reported by the investigators in three and two patients, respectively; all other serious cutaneous AEs were reported in one patient each (Table 4 ). The serious cutaneous AE in the IM IFN beta-1a group was reported as an oral sebaceous cyst considered unrelated to study treatment in a patient with a history of cigarette smoking who was admitted to the hospital for removal of the cyst (Table 4) . Among serious cutaneous AEs in the daclizumab HYP group, investigators classified ten as severe, two moderate, and two mild in severity, and three as not related to study drug (Table 4 ). In the daclizumab HYP group, six patients discontinued treatment due to a serious cutaneous AE but remained in the study, and two patients withdrew from the study due to a serious cutaneous AE but continued to be monitored (Table 4 ). All (Fig. 2) . One case of drug reaction with eosinophilia and systemic symptoms (DRESS) was reported in a patient who had previously discontinued 
DISCUSSION
In DECIDE, daclizumab HYP was associated with a higher risk of cutaneous AEs over 2-3 years of treatment compared with IM IFN beta-1a in patients with RRMS. Relevant medical history of dermatological conditions exacerbated this risk to a similar degree in both treatment groups. Consistent with these observations, the incidence of cutaneous AEs was higher with daclizumab HYP 150 mg SC (18%) than placebo (13%) in the 1-year SELECT study [6] . Cutaneous AEs reported here are distinct from injection site reactions, which are localized and temporally linked to the injection [11] .
Consistent with these findings, a recent open-label, prospective study has demonstrated a high frequency of new-onset cutaneous events associated with daclizumab HYP administration in patients with RRMS [12] .
The majority of cutaneous findings in this study were consistent both clinically and AE adverse event, DRESS drug reaction with eosinophilia and systemic symptoms, HYP high-yield process, IFN interferon, IM intramuscular, MedDRA Medical Dictionary for Regulatory Activities, NR none reported a Relationship to study drug as assessed by the investigator b The patient had previously discontinued treatment due to a non-serious cutaneous AE; however, no study action was taken as a result of the serious cutaneous AE and the patient continued in the study c The number of doses was based on an estimated date of onset because the date of onset was not reported d The patient remained on study drug and in the study e At the time this serious cutaneous AE was reported, the patient had been withdrawn from the study (consent withdrawn).
No study action was taken as a result of the serious cutaneous AE. The patient had a brain stem relapse before the onset of this serious cutaneous AE and subsequently died as a result of aspiration pneumonia histologically with an eczematous dermatitis [12] . In biopsies, cellular infiltrates in the epidermis and dermis consisted of abundant T cells, and immunohistochemistry revealed increased expression of CD56, highlighting either NK cells or CD8 ? T cells amongst them [12] . The authors suggested that cutaneous events represent pharmacologic (mechanistic) immune modulation by daclizumab HYP, rather than typical drug hypersensitivity-type reactions [12] . A previous chart review study identified a case of alopecia following the development of a severe exfoliative rash in a patient treated with intravenous daclizumab (Zenapax Ò , Roche Laboratories, Nutley, NJ, USA) [13] . Both the rash and alopecia resolved following discontinuation of daclizumab and corticosteroid treatment [13] . In the DECIDE study, alopecia was reported in 16 (2%) patients in the daclizumab HYP group (see Table 1 ). All of these cases of alopecia were mild or moderate in severity; no cases of severe alopecia were reported (see Table 3 ).
A strength of DECIDE was the inclusion of a blinded central dermatologist, which allowed for accurate monitoring and assessment of cutaneous AEs. One limitation of this study was that very few biopsies were performed on cutaneous lesions. Results from biopsies may have provided valuable information to better understand the nature of the cutaneous AEs. In addition, photographs of cutaneous AEs were limited in number and some were of insufficient quality to be useful. Interpretation of the rates of resolution of cutaneous AEs in both treatment groups may be limited by the background rate of chronic dermatologic conditions known to occur in both the general population and in patients with MS [14, 15] and by incomplete data in patients who withdrew from the study with an ongoing non-serious AE.
Because investigators were provided with cutaneous event guidelines and were made aware of this type of AE, a higher treatment rate with corticosteroids may have resulted from the distribution of these guidelines.
The potential link between the underlying mechanisms of daclizumab HYP and cutaneous AEs is unclear. Skin-resident regulatory T (T reg ) cells may counteract inflammatory T cell responses, and alterations in T reg cell function in the skin have been observed in psoriasis [16] . CD25 blockade results in both expansion of
CD56
bright natural killer cells [17, 18] and reversible declines in the number of circulating T reg cells in patients with RRMS [19, 20] . T reg cells remaining in circulation during CD25 blockade appeared to preserve the T reg phenotype [19] , although reductions in suppressive capacity have been observed [20] . As such, the relationship between reductions in T reg cells and cutaneous AEs during CD25 blockade is currently inconclusive [19, 20] .
Additional work is required to determine whether compartmental differences exist in the maintenance of organ-specific self-tolerance by T reg cells [20] . Early recognition and treatment of inflammatory skin conditions offers the best chance for reversing or limiting flares of the disease [21, 22] . Dermatologic treatment guidelines recommend topical agents, including moisturizers and topical corticosteroids, for psoriasis and eczema [23, 24] . Moisturizers maintain skin hydration and can reduce itching [23] . Topical corticosteroids are recommended to decrease inflammation, and numerous formulations are available that range in relative potency (see Table S2 ) [23, 24] . Higher-potency topical corticosteroids are generally recommended as the initial therapy for acute flares on most body parts in adults, and lower-potency agents for maintenance therapy [23, 24] . Topical treatments, including corticosteroids, are also recommended for use with systemic treatments in more extensive eczema or psoriasis [23, 24] . Systemic corticosteroids are only recommended for acute severe exacerbations of eczema [25] , and are generally contraindicated in psoriasis [26] . The overall pattern of corticosteroid treatment for cutaneous AEs in DECIDE was generally consistent with these treatment guidelines, wherein topical corticosteroids were more frequently used for mild and moderate cutaneous AEs and systemic corticosteroids for severe or serious events.
Dermatologic Perspectives of Daclizumab HYP-Related Cutaneous AEs
For the range of cutaneous AEs observed in both treatment groups in DECIDE, one must have an understanding of the overall frequency of skin diseases across world populations and the function of skin as an immunologic organ in both health and disease. Surveys have shown that eight of the most common medical problems in humans are skin conditions [27] , including eczema, which was a frequent investigator-reported diagnosis in DECIDE. Atopic eczema is also a common skin condition in up to 30% of children, where the majority outgrow eczema by early adulthood but there is also an increasing frequency of adult-onset atopic eczema across world populations [21, 28, 29] . Hence, one perspective is that a large range of common skin conditions are also seen in the DECIDE study population. Within the spectrum of cutaneous AEs in DECIDE, there was a large representation of eczema and eczema-spectrum conditions (i.e., allergic dermatitis, eczema, nummular dermatitis, and hand dermatitis) [29] , which may be classified as inflammatory skin diseases. Among patients with cutaneous Table 1 ). Although eczematous events are a nuisance, they typically tend to be reversible and do not result in skin damage or organ failure even if present for extended periods [26, 30] . Chronic rashes are likely driven by the interplay between genetic predisposition, immune response, and environmental factors (e.g., tendency for re-emergence of eczema in humans) [22] . Importantly, daclizumab HYP did not lead to cutaneous AEs that resulted in loss of skin structure or function. Most cutaneous AEs during daclizumab HYP treatment were not allergic reactions. However, a small number of drug-type hypersensitivity reactions were identified; these reactions need to be distinguished from inflammatory diseases, as it may be necessary to discontinue drugs that drive drug-type hypersensitivity reactions. 
